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Abstract
Background: The pathogenesis of pancreatic ductal adenocarcinoma (PDAC) involves multi-stage
development of molecular aberrations affecting signaling pathways that regulate cancer growth and
progression. This study was performed to gain a better understanding of the abnormal signaling that
occurs in PDAC compared with normal duct epithelia.
Methods: We performed immunohistochemistry on a tissue microarray of 26 PDAC, 13 normal
appearing adjacent pancreatic ductal epithelia, and 12 normal non-PDAC ducts. We compared the
levels of 18 signaling proteins including growth factor receptors, tumor suppressors and 13 of their
putative downstream phosphorylated (p-) signal transducers in PDAC to those in normal ductal
epithelia.
Results: The overall profiles of signaling protein expression levels, activation states and sub-
cellular distribution in PDAC cells were distinguishable from non-neoplastic ductal epithelia. The
ERK pathway activation was correlated with high levels of S2448p-mTOR (100%, p = 0.05), T389p-S6K
(100%, p = 0.02 and S235/236p-S6 (86%, p = 0.005). Additionally, T389p-S6K correlated with S727p-
STAT3 (86%, p = 0.005). Advanced tumors with lymph node metastasis were characterized by high
levels of S276p-NFκB (100%, p = 0.05) and S9p-GSK3β (100%, p = 0.05). High levels of PKBβ/AKT2,
EGFR, as well as nuclear T202/Y204p-ERK and T180/Y182p-p38 were observed in normal ducts adjacent
to PDAC compared with non-cancerous pancreas.
Conclusion: Multiple signaling proteins are activated in pancreatic duct cell carcinogenesis
including those associated with the ERK, PKB/AKT, mTOR and STAT3 pathways. The ERK pathway
activation appears also increased in duct epithelia adjacent to carcinoma, suggesting tumor micro-
environmental effects.
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Pancreatic ductal adenocarcinoma (PDAC) is the most
common malignant tumor of the human pancreas. PDAC
patients have one of the worst prognoses among all cancer
types with a 5-year survival rate of less than 5%. Despite
significant advances during the last decade in our molec-
ular knowledge on this disease, the prognosis and man-
agement of PDAC patients have remained unchanged
[1,2]. The most common genetic aberrations in pancreatic
duct cell carcinogenesis involve the activation of KRAS
oncogene and inactivation of tumor suppressor genes
p16/CDKN2, p53 and SMAD4/DPC4 [3]. Less frequently
altered genes in PDAC are the amplification of growth fac-
tor receptors EGFR and HER2 [4,5], and the survival sign-
aling transducer PKBβ/AKT2 [6]. Additionally, the
molecular deregulation of the tyrosine kinase receptor c-
MET has been associated with enhanced transcript levels
[7]. The protein products of these genes play important
regulatory roles in cell proliferation, survival, motility,
invasion and differentiation. There is increasing realiza-
tion that the biochemical activities and cellular functions
of these genes constitute part of a complex network of
interacting signaling pathways [8]. Activities of these path-
ways are highly dependent on the reversible phosphoryla-
tion of tyrosine, threonine or serine residues of signal
transduction proteins.
Despite a significant gain of knowledge on genes that are
differentially expressed in PDAC compared with normal
pancreas or duct cells, the associated changes in signal
transduction networks have not yet been extensively char-
acterized. Studies on the activation of singular pathways
by immunohistochemistry (IHC) with phosphorylation-
specific antibodies have been reported for PKB/AKT
[9,10], p70/S6K [11], NFκB [12,13] and STAT3 [14].
These signaling proteins are potentially major signaling
hubs downstream of growth factor receptors that are over-
expressed in proportions of PDAC including EGFR (31%
to 58%) [5,15,16], HER2 (20%) [4], c-MET/hepatocyte
growth factor receptor (78%) [17], c-KIT/stem cell recep-
tor (38%) [18]. However, the IHC analyses performed in
these studies rarely included pathway activities in normal
pancreatic cellular compartments including the centroaci-
nar, duct or ductular, acinar and islet cells. These compo-
nents may contain subpopulations of cells that are
pancreatic progenitor cells as well as the cell of origin for
PDAC [19-21]. The survival of the ductal epithelia has
been associated with activated ERK in an inflammatory
environment of hereditary pancreatitis, a risk factor for
PDAC [22].
To better understand the activation of tyrosine and serine/
threonine phosphorylated proteins, we have used IHC
analysis to evaluate the levels and activation state of sev-
eral signaling pathways including the ERK, SRC, STAT3,
PTEN/PKB, mTOR/S6K/S6, β-catenin (βCAT) and SMAD4
in PDAC cells and epithelia of normal pancreas.
Methods
Tissue material
This study has been approved by the Research Ethics
Board of the University Health Network (Toronto, ON,
Canada) in compliance with applicable national Tri-
Council ethics principles. The formalin-fixed and paraffin
embedded (FFPE) samples used in this study were tumor
and adjacent normal pancreatic tissue obtained within 30
minutes after Whipple's resection for pancreatic ductal
adenocarcinoma (PDAC) or non-PDAC conditions. The
FFPE blocks were made from thin cross sections of tissues
collected for snap-frozen tumor banking and were ini-
tially intended for a histological quality check of the
banked tissue. These samples were particularly suitable for
this study due to their limited delay between sampling
and fixation.
Tissue microarray (TMA) construction
Histology was reviewed to assure the correct diagnosis of
the 26 PDAC specimens and 12 specimens that were con-
sidered "normal" pancreas from patients with non-pan-
creatic conditions (e.g. Ampulla of Vater, bile duct and
stomach cancers) [see Additional file 1]. The clinicopatho-
logical parameters of individual cases are listed in an addi-
tional file [see Additional file 2]. H&E slides were used to
guide the selection of representative 1.5 mm diameter
cores from paraffin blocks containing viable tumor areas
and morphologically normal pancreatic parenchyma. The
cores were constructed into a tissue microarray (TMA)
using a manual tissue arrayer (Beecher Instruments, Sun
Prairie, WI). The final TMA contained 67 of 71 (94.3%)
cores, (four cores were lost during processing) and each
PDAC case was represented by at least one core [see Addi-
tional file 3]. Results are reported on 26 tumor cores (T),
13 cores containing adjacent normal parenchyma and
non-neoplastic ducts (Dt), and 12 cores containing paren-
chyma with non-neoplastic tissue from non-PDAC condi-
tions (D).
Immunohistochemistry
Antibodies and staining methods are summarized in an
additional file [see Additional file 2]. Microwave antigen
retrieval was performed for all immunostains except CK7,
EGFR and p-S6 which were treated with pepsin digestion.
Secondary antibodies (anti-mouse and anti-rabbit) were
used as provided by the IDetect Ultra HRP system (ID
Labs, London, ON). Goat polyclonal antibody (biotin-
conjugated anti-goat IgG, 1:300 dilution), NovaRed per-
oxidase substrate and hematoxylin counterstain were pur-
chased from Vector Laboratories (Burlingame, CA). A
negative control slide was processed with a mix of pooledPage 2 of 10
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tion [see Additional file 1].
IHC scoring system
The immunostained slides were scanned using an Aperio
CS Scanner (Vista, CA) at 20× magnification. Either slides
or digital images were used for scoring by three independ-
ent evaluators (NAP, JS, VI) without prior knowledge of
the core source or stained target antigen. Final scores were
based on a consensus of the three evaluators. A single
intensity score was obtained since the intensity of staining
within each core was mostly homogeneous. Intensity was
scored as 0 for absence of staining, 1 for weak, 2 for mod-
erate, and 3 for strong staining. Scores were recorded for
the different cell types as well as their nuclear and cyto-
plasmic compartments. EGFR and MET receptor were
scored for their plasma membrane staining only.
Statistical analysis
Unsupervised hierarchical clustering using the agglomera-
tion rule average linkage placed cases and antibodies next
to each other if they were most similar in their IHC pro-
files (free software Genesis [23]). The relationship of two
categorical variables was calculated using Fisher's exact
test. Data of categorical variables were arbitrarily split into
low and high groups to maximize statistical power
obtained by equalizing the number of samples in each
groups. The strength of the relationship between two var-
iables was calculated using Spearman's rank correlation
coefficient, Rho (ρ). No adjustment for multiple testing
was done. Statistical analyses were performed in SAS Ver-
sion 9.1 (SAS Institute, Cary, NC).
Results
Differential expression of signaling proteins in PDAC
A heat map in Figure 1 shows relative expression levels of
eight signaling proteins. The plasma membrane expres-
sion of EGFR (p = 0.02) and MET receptor (p < 0.0001)
and the cytoplasmic proteins ADAM9 (p < 0.001), SRC (p
< 0.0001), PKBβ (p = 0.0005) and βCAT (p = 0.005) were
significantly higher in PDAC cells than in histologically
normal ducts. In contrast, levels of the two known tumor
suppressor genes cytoplasmic PTEN (p = 0.01) and
nuclear SMAD4 (p = 0.0005) were significantly lower in
PDAC cells than in normal ducts. The p-values of Fisher's
exact tests were calculated using proportions of PDAC
cells and ducts that expressed high levels of proteins [see
Additional file 3]. Unsupervised hierarchical clustering
Signaling proteins in PDAC and ductal epitheliaFigure 1
Signaling proteins in PDAC and ductal epithelia. Signaling protein levels in the TMA specimens are represented in a 
grayscale map of IHC intensity levels. Tissue cores are identified as tumor (T), ducts from normal pancreas in PDAC (Dt), or 
ducts from non-PDAC (D). Array position is designated using x-y coordinates (A-J, 1–8), and specimens derived from the same 
case have identical nomenclature (T coordinates/Dt coordinates). Protein distribution is cytoplasmic unless designated as 
nuclear (N-). Common branches show expression similarities in specimens and proteins using an unsupervised hierarchical 
clustering analysis. The two largest branches contain specimens of tumor (a) and histologically normal ducts (b).Page 3 of 10
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adjacent to PDAC and non-PDAC pancreas (group b). As
expected, cytokeratin 7 was expressed in all PDAC cells
and normal ducts (results not shown).
Cytoplasmic activated protein profiles
An unsupervised clustering of cytoplasmic activated pro-
tein levels shows that tumor specimens (Figure 2A, group
a) are more similar to each other than to histologically
normal ducts (group b). Only five of twenty five speci-
mens of normal ducts were misclassified as tumor, while
none of the tumors were misclassified as normal ducts.
The cytoplasmic levels of activated p-ERK (p < 0.001), p-
SRC (p = 0.0005), T308p-PKB (p < 0.0001), p-p38 (p =
0.02), and their putative downstream substrates p-JNK (p
< 0.0001), S727p-STAT3 (p = 0.005), Y705p-STAT3 (p =
0.0005), p-GSK3β (p = 0.006), p-RAF (p = 0.01) and p-
mTOR (p = 0.05) were significantly higher in PDAC cells
than in ducts. Degradation-targeted p-βCAT levels signifi-
cantly decreased (p < 0.0001) in PDAC cells compared
with ducts, consistent with the observation of an accumu-
lation of βCAT in PDAC compared with ducts (Figure 1).
The four cytoplasmic proteins, S473p-PKB, p-S6K, p-S6 and
p-NFκB were similarly expressed in PDAC cells and ducts
(Table 1). Although the cytoplasm is the known cellular
compartment of activity for the mTOR/S6K/S6 pathway
(Figure 2B, i and 2B, ii), a subset of activated signaling
proteins are also known to translocate into the nucleus.
For example, p-ERK was detected at high levels in the cyto-
plasm as well as the nuclei of cancer cells (Figure 2B, iii).
Low levels of nuclear p-ERK were detected in normal pan-
creatic ductal cells and acinar (Figure 2B, iv).
Nuclear activated protein profiles
Since many signaling proteins translocate into the nucleus
to serve as transcription factors after being activated by
phosphorylation, we explored their profiles in PDAC cells
compared with histologically normal ductal epithelia. An
unsupervised clustering of the nuclear activated protein
levels showed an absence of clustering between tumor
and normal ducts (Figure 3). Levels of nuclear activated
proteins, including p-NFκB, p-STAT3, p-βCAT, p-GSK3β
and T308p-PKB, were similarly expressed in PDAC cells and
normal ducts. However, the levels of four proteins, p-ERK
(p = 0.001), p-p38 (p = 0.004), p-JNK (p = 0.01), and
S473p-PKB (p = 0.001) were significantly higher in nuclei
of PDAC cells than in normal ducts (Table 1). Cancer cells
also displayed significant moderate to strong relation-
ships between cytoplasmic and nuclear levels for several
proteins: p-ERK (ρ = 0.72, p < 0.001), p-p38 (ρ = 0.56, p
= 0.004), T308p-PKB (ρ = 0.52, p = 0.007), SMAD4 (ρ =
0.63, p < 0.001) and PTEN (ρ = 0.87, p < 0.001). These
associations were absent in ductal epithelia from non-
PDAC specimens except for an association of cytoplasmic
and nuclear levels for p-p38 (ρ = 0.61, p < 0.001) in the
ductal epithelia adjacent to PDAC [see Additional file 4].
Protein-protein and clinicopathological relationships
Table 2 shows that proportions of PDAC specimens char-
acterized by the ERK pathway activation were associated
with all specimens of high p-mTOR levels (100%, p =
0.05), and its downstream substrates p-S6K (100%, p =
0.02), and a proportion of specimens with high p-S6
(86%, p = 0.005). The activation of p-S6K also correlated
with high levels of S727p-STAT3 (86%, p = 0.005) and
shows a positive trend with high levels of T308p-PKB
(100%, 0.06). The activation of p-STAT3 correlated with
high levels of PKBβ (59%, p = 0.004) and the presence of
SMAD4 (70%, 0.02). An association was observed
between high levels of T308p-PKB and p-JNK (80%, p =
0.05). High levels of inactive p-RAF was correlated with
PKBβ (82%, p = 0.009), PTEN (91%, p = 0.01) and p-
βCAT (91%, p = 0.01). Protein levels were compared with
Table 1: Activated protein levels in PDAC compared with 
histologically normal duct cells
Marker High IHC score PDAC (%) Duct (%) p-value
Cytoplasm
p-JNK ≥ 2 77 4 <0.0001
p-ERK ≥ 2 62 8 <0.0001
p-SRC ≥ 2 73 40 0.0005
S727p-STAT3 ≥ 3 38 4 0.005
T308p-PKB ≥ 2 69 12 <0.0001
p-S6K ≥2 27 16 0.5
S473p-PKB ≥2 15 0 0.1
p-NFκB ≥2 19 4 0.2
p-S6 ≥2 54 40 0.4
p-p38 ≥ 2 65 20 0.002
Y705p-STAT3 ≥ 2 85 26 0.0005
p-GSK3β ≥ 3 50 12 0.006
p-mTOR ≥ 3 19 0 0.05
p-RAF ≥ 3 62 24 0.01
p-βCAT ≥ 2 42 96 <0.0001
Nucleus
p-NFκB ≥3 50 56 1
p-ERK ≥ 3 62 16 0.001
p-p38 ≥ 3 62 20 0.004
p-JNK ≥ 3 26 0 0.01
T308p-PKB ≥3 27 8 0.1
S727p-STAT3 ≥2 77 80 1
S473p-PKB ≥ 2 62 16 0.001
Y705p-STAT3 ≥2 69 56 0.4
p-βCAT ≥2 35 32 1
p-GSK3β ≥1 23 20 1
Proportions of PDAC and duct specimens are split into low and high 
groups of IHC scores. The results of Fisher's exact test are 
highlighted for significant differences (p ≤ 0.05) and trends (p = 0.06). 
Listed are percentages of specimens with high protein levels based on 
a total of 26 PDAC (T specimens) and 25 normal ducts (D and Dt 
specimens).Page 4 of 10
(page number not for citation purposes)
BMC Cancer 2008, 8:43 http://www.biomedcentral.com/1471-2407/8/43
Page 5 of 10
(page number not for citation purposes)
Cytoplasmic protein activity levelsFigure 2
Cytoplasmic protein activity levels. (A) Cytoplasmic activated protein profiles are represented by a grayscale map of IHC 
intensity levels. The two largest branches derived from an unsupervised hierarchical clustering analysis show similarities in 
tumor specimens (a) and histologically normal ducts (b). (B) Representative IHC images of activated mTOR (i, ii) and ERK (iii, 
iv) from the TMA of tumor (T-B4/A4, i, iii) and ducts of non-PDAC pancreas (D-J3, ii, iv, arrows). A typical duct is digitally 
enlarged (insert).
BMC Cancer 2008, 8:43 http://www.biomedcentral.com/1471-2407/8/43clinicopathological characteristics of tumors. There was
no significant association between tumor grade and indi-
vidual protein levels (p-value > 0.06, Fisher's exact test,
results not shown). However, advanced stage (III and IV)
showed a trend in association with higher levels of βCAT
(p = 0.04), p-NFκB (p = 0.05) and p-GSK3β (p = 0.05). In
contrast, high levels of p-STAT3 (p = 0.01) and loss of
PTEN (p = 0.01) appeared not to be associated with cancer
progression. Table 3 lists the distribution of PDAC stages
that showed trends in associations with proteins levels.
Nuclear protein activity levelsFigure 3
Nuclear protein activity levels. Nuclear activated protein profiles are represented by a grayscale map of IHC intensity lev-
els. Common branches show protein level similarities in specimens and proteins from an unsupervised hierarchical clustering 
analysis.
Table 2: Associations of cytoplasmic protein levels
Corresponding protein % specimen (number)
Protein Low High p-value
High p-ERK
p-mTOR 48 (10/21) 100 (5/5) 0.05
p-S6K 47 (9/19) 100 (7/7) 0.02
p-S6 27 (3/11) 86 (12/14) 0.005
HighS727p-STAT3
PKBβ 0 (0/9) 59 (10/17) 0.004
p-S6K 21 (4/19) 86 (6/7) 0.005
SMAD4 19 (3/16) 70 (7/10) 0.02
HighT308p-PKB
p-JNK 33 (2/6) 80 (16/20) 0.05
p-S6K 58 (11/19) 100 (7/7) 0.06
High p-RAF
PKBβ 22 (2/9) 82 (14/17) 0.009
PTEN 40 (6/15) 91 (10/11) 0.01
p-βCAT 40 (6/15) 91 (10/11) 0.01
Listed are high levels of targeted cytoplasmic proteins (highlighted) that significantly associated with either low or high levels for corresponding 
cytoplasmic proteins (Fisher's exact test, p ≤ 0.05), and trends (p = 0.06).Page 6 of 10
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A subset of the signaling proteins examined in this study
differentially characterized histologically normal ducts
adjacent to PDAC compared with ducts in non-PDAC
pancreas (Figure 4A). Mean levels of five proteins, cyto-
plasmic PKBβ (p = 0.03) and p-S6 (0.03), and nuclear p-
GSK3β (p = 0.008), p-ERK (p = 0.04) and p-p38 (p =
0.03), were significantly higher in ducts adjacent to PDAC
than in non-PDAC pancreas [see Additional file 5]. EGFR
levels showed a tendency (p = 0.055) to be higher in ducts
adjacent to PDAC compared with non-PDAC pancreas.
Centroacinar cells, which are the terminal ducts lining the
centre of the acini, as expected showed a protein profile
that was similar compared with larger ducts (Figure 4B).
The seven proteins, CK7, ADAM9, EGFR, p-βCAT, p-
GSK3β, p-mTOR and p-p38 were present in both centro-
acinar and ductal components (Figure 4C). The high
expression of p-βCAT, EGFR and ADAM9 characterized
islet cells, and relatively lower levels of all seven proteins
characterized acinar cells.
Discussion
In this study, we used immunohistochemistry (IHC) anal-
ysis to profile multiple signaling pathways involved in
growth and progression of PDAC. To our knowledge, this
is the most comprehensive analysis of signaling protein
profiles in PDAC cells compared with normal pancreatic
duct cells. To confirm the validity of our study, we showed
similar frequencies of loss of PTEN and SMAD4 expres-
sion in our PDAC samples [24,25], and higher levels of
ADAM9 and βCAT in tumor compared with normal ducts
as previously reported [1,26]. Our results suggest that
higher levels of PTEN (8/9 cases) and lower STAT3 activa-
tion (6/6 cases) were associated with advanced PDAC.
Our results reveal that the predominantly activated signal-
ing proteins in PDAC include those associated with the
ERK, mTOR, STAT3, PKB and p38 pathways (Figure 5).
The trend for associations in (phospho-) protein levels
between ERK and the mTOR/S6K/S6 pathway, as well as
S6K and PKB or STAT3 suggest a co-activation of these
pathways or their crosstalk in PDAC. We propose that fur-
ther evaluations of ERK and mTOR pathways in PDAC as
possible targets for drug combinations are warranted,
since single molecule-directed strategies, such as the EGFR
inhibitor erlotinib only had a limited effect on patient sur-
vival [27].
Our results further suggest that PKB activity lacked signif-
icant association with its antagonistic regulator PTEN as
well as with downstream PKB substrates including GSK3β,
RAF and mTOR. Previous studies reported that high levels
of PKBβ (17/61 cases) [10] or loss of PTEN (3/9 cases)
were associated with enhanced PKB activity [28] in PDAC.
Additionally, the loss of PTEN was found only in a subset
of PDAC specimens characterized by enhanced PKBβ
activity (2/12 cases) [29]. These inconsistencies may arise
from methodological differences (e.g. varying pre-fixation
time with impact on phosphorylation states) [30], or the
limited number of cases included in previous studies and
merit further evaluation.
The levels of a subset of signaling pathways including p-
ERK, p-p38, PKBβ or EGFR were enhanced in histologi-
cally normal duct cells in PDAC compared with non-
PDAC pancreas. This is consistent with a pro-survival role
of ERK and JNK in ductal epithelia of a murine hereditary
pancreatitis model [22], and of enhanced EGFR expres-
sion in chronic pancreatitis [31]. It is conceivable that the
activation of these signaling pathways could contribute to
early stages of duct cell carcinogenesis or reflect tumor
micro-environmental effects of PDAC.
Conclusion
Our observations suggest that multiple signaling proteins
are activated in pancreatic duct cell carcinogenesis includ-
Table 3: Protein levels which characterized advanced PDAC stage
Number of specimens (%)
Marker Low protein level High protein level p-value
I II III IV I II III IV
Cytoplasm
PTEN 1 (7) 8 (53) 6 (40) 0 1 (9) 0 8 (73) 2 (18) 0.01
βCAT 1 (6) 8 (50) 5 (31) 2 (13) 0 1 (10) 9 (90) 0 0.04
p-NFκB 1 (5) 9 (47) 7 (37) 2(11) 0 0 5 (100) 0 0.05
Nucleus
Y705p-STAT3 0 0 6 (75) 2 (25) 1 (6) 9 (50) 8 (44) 0 0.01
p-GSK3β 1 (5) 9 (45) 8 (40) 2 (10) 0 0 6 (100) 0 0.05
Listed are tumors of stage I to IV, and their proportions (%) in low/high protein levels. Advanced PDAC stage (III and IV) associated with high 
protein levels (PTEN, βCAT, p-NFκB and p-GSK3β) and low p-STAT3 levels (Fisher's exact test, p ≤ 0.05).Page 7 of 10
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pathways. Activation of the ERK pathway also appears
increased in duct epithelia adjacent to carcinoma, suggest-
ing a tumor micro-environmental effect.
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Ductal epithelia and the pancreas parenchymaFigure 4
Ductal epithelia and the pancreas parenchyma. (A) The profile of six proteins shows significant differences in mean pro-
tein levels in ducts of normal pancreas in PDAC compared with ducts in non-PDAC: PKBβ (p = 0.03), nuclear (N-) p-GSK3β (p 
= 0.008), EGFR (p = 0.055), N-p-ERK (p = 0.04), N-p-p38 (p = 0.03) and p-S6 (p = 0.03). (B) A representative image of centro-
acinar cells (arrows) and larger ducts (arrowheads) shows positive staining for p-mTOR. (C) A subset of the signaling proteins 
shows differential staining among the cellular components of the pancreas.Page 8 of 10
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